Inhibiting the activity of the NF-κB pathway can increase the susceptibility of those with BC to antitumour medications and endocrine therapy by downregulating the expression of NF-κB pathway proteins in MCF-7 cells35. This evidence concerns the gene NFKB1 and breast cancer.